Interpretive reading of the non-fermenting gram-negative bacilli antibiogram;Lectura interpretada del antibiograma de bacilos gramnegativos no fermentadores

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 10, 2010, Pages 726-736

  Vila, Jordi ^a   Marco, Francesc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

A. baumannii; P. aeruginosa; Resistance; S. maltophilia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE AMPC; CARBAPENEM; DNA TOPOISOMERASE; METALLO BETA LACTAMASE; PORIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; ENZYME SYNTHESIS; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERMEABILITY; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN TARGETING; PSEUDOMONAS AERUGINOSA; REVIEW; STENOTROPHOMONAS MALTOPHILIA;

EID: 78649685453     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2010.05.001     Document Type: Article

References (103)

1. S.T. Micek, A.E. Lloyd, D.J. Ritchie, R.M. Reichley, V.J. Fraser, and M.H. Kollef Pseudomonas aeruginosa bloodstream infection: importance of appropiate initial antimicrobial treatment Antimicrob Agents Chemother 49 2005 1306 1311
2. D.M. Livermore Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34 2002 634 640
3. P.D. Lister, D.J. Wolter, and N.D. Hanson Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms Clin Microbiol Rev 22 2009 582 610
4. N. Mesaros, P. Nordmann, P. Plsiat, M. Roussel-Delvallez, J. Van Eldere, and Y. Glupczynski Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millenium Clin Microbiol Infect 13 2007 560 578
5. G. Vedel Simple method to determine β-lactam resistance phenotypes in Pseudomonas aeruginosa using the disc agar diffusion test J Antimicrob Chemother 56 2005 657 664
6. D.M. Livermore Penicillin-binding proteins, porins and outer-membrane permeability of carbenicillin-resistant and susceptible strains of Pseudomonas aeruginosa J Med Microbiol 18 1984 261 270
7. D.M. Livermore Of Pseudomonas porins, pumps and carbapenems J Antimicrob Chemother 47 2001 247 250
8. R.E. Hancock, and F.S. Brinkman Function of pseudomonas porins in uptake and efflux Annu Rev Microbiol 56 2002 17 38
9. D.M. Livermore βlactamases in laboratory and clinical resistance Clin Microbiol Rev 8 1995 557 584
10. N. Bagge, O. Ciofu, M. Hentzer, J.I. Campbell, M. Givskov, and N. Hoiby Constitutive high expression of chromosomal β-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD Antimicrob Agents Chemother 46 2002 3406 3411
11. T.Y. Langaee, M. Dargis, and A. Huletsky Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC beta-lactamase expression Antimicrob Agents Chemother 42 1998 3296 3300
12. C. Juan, M.D. Maci, O. Gutirrez, C. Vidal, J.L. Prez, and A. Oliver Molecular mechanisms of β-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains Antimicrob Agents Chemother 49 2005 4733 4738
13. B. Moya, C. Juan, S. Albert, J.L. Prez, and A. Oliver Benefit of having multiple ampD genes for acquiring β-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa Antimicrob Agents Chemother 52 2008 3694 3700
14. B. Moya, A. Dotsch, C. Juan, J. Blzquez, L. Zamorano, and S. Haussler Beta-lactam resistance response triggered by inactivation of nonessential penicillin-binding protein PLoS Pathog 5 2009 e1000353
15. F. Bert, C. Branger, and N. Lambert-Zechovsky Identification of PSE and OXA β-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism J Antimicrob Chemother 50 2002 11 18
16. F. Sanschagrin, N. Bejaoui, and R.C. Levesque Structure of CARB-4 and AER-1 carbenicillin hydrolizing β-lactamases Antimicrob Agents Chemother 42 1998 1966 1972
17. T. Strateva, and D. Yordanov Pseudomonas aeruginosaa phenomenon of bacterial resistance J Med Microbiol 58 2009 1133 1148
18. GES-1 and fused product of aac(3)-Ib/aac(6′)-ib′ gene cassettes in Pseudomonas aeruginosa Antimicrob Agents Chemother 46 2002 638 645
19. L. Poirel, G.F. Weldhagen, C. De Champs, and P. Nordmann A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa J Antimicrob Chemother 49 2002 561 565
20. L. Poirel, T. Naas, and P. Nordmann Diversity, epidemiology, and genetics of class D beta-lactamases Antimicrob Agents Chemother 54 2010 24 38
21. D. Aubert, L. Poirel, J. Chevalier, S. Lotard, J.M. Pags, and P. Nordmann Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa Antimicrob Agents Chemother 45 2001 1615 1620
22. Danel F, Hall LMC, Gur D, Livermore DM. OXA-15, an extended-spectrum variant of OXA-2 β-lactamase, isolated from Pseudomonas aeruginosa strain. Antimicrob Agents Chemother. 1998; 42: 311722
23. L. Poirel, P. Gerome, C. De Champs, J. Stephanazzi, T. Naas, and P. Nordmann Integron-located oxa-32 gene cassette encoding extenden-spectrum variant of OXA-2 β-lactamase from Pseudomonas aeruginosa Antimicrob Agents Chemother 46 2002 566 569
24. L.N. Philippon, T. Naas, A.-T. Bouthors, V. Barakett, and P. Nordmann OXA-18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosa Antimicrob Agents Chemother 41 1997 2188 2195
25. M.A. Toleman, K. Rolston, T.N. Jones, and T.R. Walsh Molecular and biochemical characterization of OXA-45, an extended-spectrum clas 2d' β-lactamase in Pseudomonas aeruginosa Antimicrob Agents Chemother 47 2003 2859 2863
26. E. Sevillano, L. Gallego, and J.M. Garca-Lobo First detection of the OXA-40 carbapenemase in Pseudomonas aeruginosa isolates, located on a plasmid also found in A. baumannii Pathol Biol 57 2009 493 495
27. P. Nordmann, and L. Poirel Emerging carbapenemases in Gram-negative aerobes Clin Microbiol Infect 8 2002 321 331
28. K. Senda, Y. Arakawa, K. Nakashima, H. Ito, S. Ichiyama, and K. Shimokata Multifocal outbreaks of metallo-β-lactamase producing Pseudomonas aeruginosa resistant to broad spectrum β-lactams, including carbapenems Antimicrob Agents Chemother 40 1996 349 353
29. Vim, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate Antimicrob Agents Chemother 43 1999 1584 1590
30. G. Prats, E. Mir, B. Mirelis, L. Poirel, S. Bellais, and P. Nordmann First isolation of a carbapenem-hydrolyzing β-lactamase in Pseudomonas aeruginosa in Spain Antimicrob Agents Chemother 46 2002 932 933
31. C. Pea, C. Suarez, F. Tubau, O. Gutierrez, A. Domnguez, and A. Oliver Nosocomial spread of Pseudomonas aeruginosa producing the metallo-β- lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications Clin Microbiol Infect 13 2007 1026 1029
32. O. Gutirrez, C. Juan, E. Cercenado, F. Navarro, E. Bouza, and P. Coll Carbapenem resistance in Pseudomonas aeruginosa from Spanish hospitals: Molecular epidemiology and mechanisms Antimicrob Agents Chemother 51 2007 4329 4335
33. M.C. Rodriguez, B. Ruiz del, C. Rodrguez-Mirones, M. Romo, I. Monteagudo, and L. Martnez-Martnez Caracterizacin molecular de aislados clnicos de Pseudomonas aeruginosa productores de la metalobetalactamasa VIM-2 en Cantabria, España Enferm Infecc Microbiol Clin 28 2010 99 103
34. C. Juan, A. Beceiro, O. Gutirrez, S. Albert, M. Garau, and J.L. Prez Characterization of the new metallo-β-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain Antimicrob Agents Chemother 52 2008 3589 3596
35. M.A. Toleman, A.M. Simm, T.A. Murphy, A.C. Gales, D.J. Biedenbach, and R.N. Jones Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme J Antimicrob Chemother 50 2002 673 679
36. GIM1, encoding a new subclass of metallo-β-lactamase Antimicrob Agents Chemother 48 2004 4654 4661
37. A. El Salabi, M.A. Toleman, J. Weeks, T. Bruderer, R. Frei, and T.R. Walsh First report of the metallo-β-lactamase SPM-1 in Europe Antimicrob Agents Chemother 54 2010 582
38. S. Sakyo, H. Timita, K. Tanimoto, S. Fujimoto, and Y. Ike Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa J Antibiot 59 2006 220 228
39. F.J. Prez, C. Gimeno, D. Navarro, and J. Garca-de-Lomas Meropenem permeation through the outer membrane of Pseudomonas aeruginosa can involve pathways other than OprD porin channel Chemotherapy 42 1996 210 214
40. C.K. Stover, X.Q. Phan, A.L. Erwin, S.D. Mizoguchi, P. Warrener, and M.J. Hickey Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen Nature 406 2000 959 964
41. C. Llanes, D. Hocquet, C. Vogne, D. Benali-baitich, C. Neuwirth, and P. Plesiat Clinical strains of Pseudomonas aeruginosa overproducing; exAB-OprM and MexXY efflux pumps simultaneously Antimicrob Agents Chemother 48 2004 1797 1802
42. K. Saito, H. Yoneyama, and T. Nakae nal-B type mutations causing the overexpresion on the MexA-MexB-Oprm efflux pump are located in the mexR gene of the Pseudomonas aeruginosa chromosome FEMS Microbiol Lett 179 1999 67 72
43. Y. Doi, and Y. Arakawa 16S ribosomal RNA methylation: emerging resistance mechanisms against aminoglycosides Clin Infect Dis 45 2007 88 94
44. Y. Doi, and Y. Arakawa 16S ribosomal RNA methylation: emerging resistance mechanisms against aminoglycosides Antimicrob Agents Chemother 41 1997 785 790
45. K. Yokoyama, Y. Doi, K. Yamane, H. Kurokawa, N. Shibata, and K. Shibayama Acquisition of 16 S rRNA methylase gene in Pseudomonas aeruginosa Lancet 362 2003 1188 1893
46. N. Masuda, E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino Substrates specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa Antimicrob Agents Chemother 44 2000 3322 3327
47. D.L. MacLeod, L.E. Nelson, R.M. Shawar, B.B. Lin, L.G. Lockwood, and J.E. Dirks Aminoglycoside resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment J Infect Dis 181 2000 1180 1184
48. F. El'Garch, K. Jeannot, D. Hocquet, C. Llanes-Barakat, and P. Plesiat Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides Antimicrob Agents Chemother 51 2007 1016 1021
49. D.C. Hooper Emerging mechanisms of fluoroquinolone resistance Emerg Infect Dis 7 2001 337 341
50. M. Nakano, T. Deguchi, T. Kawamura, M. Yasuda, M. Kimura, and Y. Okano Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa Antimicrob Agents Chemother 41 1997 2289 2291
51. S. Jalal, and B. Wretlind Mechanisms of quinolone sresistance in clinical strains of Pseudomonas aeruginosa Microb Drug Resist 4 1998 257 261
52. H. Nikaido, and D.G. Thanassi Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracylines and fluoroquinolones as examples Antimicrob Agents Chemother 37 1993 1393 1399
53. A. Nakajima, Y. Sugimoto, H. Yoneyama, and T. Nakae High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation Microbiol Immunol 46 2002 391 395
54. L. Dijskhoorn, A. Nemec, and H. Siefert An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii Nat Rev Microbiol 5 2007 939 951
55. J. Vila, and J. Pachn Therapeutic options for Acinetobacter baumannii infections Expert Opin Pharmacother 9 2008 587 599
56. J. Pachn, and J. Vila Treatment of multiresistant Acinetobacter baumannii infections Curr Op Invest Drugs 10 2009 150 156
57. K. Sato, and T. Nakae Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance J Antimicrob Chemother 28 1991 35 45
58. L. Damier-Piolle, S. Magnet, S. Bremont, T. Lambert, P. Courvalin, and I.J.K. Ade A resistant nodulation cel division pump effluxing multiple antibiotics in Acinetobacter baumannii Antimicrob Agents Chemother 52 2008 557 562
59. I. Roca, S. Mart, P.A. Espinal, P. Martnez, I. Gibert, and J. Vila CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii Antimicrob Agents Chemother 53 2009 4013 4014
60. A. Ribera, I. Roca, J. Ruiz, I. Gibert, and J. Vila Partial characterization of a transposon containing the tet(A) determinant in a clinicl isolate of Acinetobacter baumannii J Antimicrob Chemother 52 2003 477 480
61. J. Vila, F. Marco, M.A. Marcos, S. Abdalla, Y. Vergara, and R. Reig In Vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii Antimicrob Agents Chemother 37 1993 138 141
62. M. Devaud, F.H. Kayser, and B. Bachi Transposon mediated multiple antibiotic resistance in Acinetobacter strains Antimicrob Agents Chemother 22 1982 323 329
63. J. Vila, M. Navia, J. Ruiz, and C. Casals Cloning and nucleotide sequence anlisis of a gene encoding an OXA-derived beta-lactamase in Acinetobacter baumannii Antimicrob Agents Chemother 41 1997 2757 2759
64. G. Paul, M.L. Joly-Guillou, E. Bergogne-Berezin, P. Nvot, and A. Philippon Novel carbenicillin-hydrolyzing beta-lactamase (CARB-5) from Acinetobacter calcoaceticus var. anitratus FEMS Microbiol Lett 59 1989 45 50
65. L. Poirel, S. Corvec, M. Rapoport, P. Mugnier, A. Petroni, and F. Pasteran Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina Antimicrob Agents Chemother 51 2007 2179 2184
66. G. Bou, and J. Martnez-Beltrn Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC beta-lactamase in Acinetobacter baumannii Antimicrob Agents Chemother 44 2000 428 432
67. C. Danes, M.M. Navia, J. Ruiz, F. Marco, A. Jurado, and M.T. Jimenez de Anta Distribution of beta-lactamases in Acinetobacter baumannii clinical isolates and the effect of Syn 2190 (AmpC inhibitor) in the MICs of different beta-lactam antibiotics J Antimicrob Chemother 50 2002 261 263
68. S. Corvec, N. Caroff, E. Espaze, C. Giraudeau, H. Drugeon, and A. Reynaud AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical isolates J Antimicrob Chemother 52 2003 629 635
69. M. Ruiz, S. Mart, F. Fernndez-Cuenca, A. Pascual, and J. Vila Prevalence of ISAba1 in epidemiologically unrelated Acinetobacter baumannii clinical isolates FEMS Microbiol Lett 274 2007 63 66
70. J.F. Turton, M.E. Ward, N. Woodford, M.E. Kaufmann, R. Piker, and D.M. Livermore The role of ISAba1 in expression of OXA carbapenemse genes in Acinetobacter baumannii FEMS Microbiol Lett 258 2006 72 77
71. H. Segal, E.C. Nelson, and B.G. Elisha Genetic environment and transcription of ampC in Acinetobacter baumanii clinical isolate Antimicrob Agents Chemother 48 2004 612 614
72. H. Vahabogl, R. Oztrk, G. Aygn, F. Coskunkan, A. Yaman, and A. Kaygusuz Widespread detection of PER-1-type extended spectrum beta-lactamases hmong nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multi-center study Antimicrob Agents Chemother 41 1997 2265 2269
73. D. Yong, H. Shin, S. Kim, Y. Lim, J.H. Yum, and K. Lee High prevalence of PER-1 extended-spectrum beta-lactamase-producing Acinetobacter spp in Korea Antimicrob Agents Chemother 47 2003 1749 1751
74. T. Naas, P. Nordmann, and A. Heidt Inter-country transfer or PER-1 extended-spectrum beta-lactamase-producing Acinetobacter baumannii from Romania Inter J Antimicrob Agents 29 2007 226 228
75. T. Naas, P. Bogaerts, C. Bauraing, Y. Delgheldre, Y. Glupczynski, and P. Nordmann Emergence of PER and VEB extended-spectrum beta-lactamases in Acinetobacter baumannii in Belgium J Antimicrob Chemother 58 2006 178 182
76. PER-2 beta-lactamase genes in clinicl isolates from Bolivian hospitals J Antimicrob Chemother 57 2006 975 978
77. M.M. Navia, J. Ruiz, and J. Vila Characterization o fan integron carrying a new class D beta-lactamase (OXA-37) in Acinetobacter baumannii Microb Drug Resist 8 2002 261 265
78. N. Nagano, Y. Nagano, C. Cordevant, N. Shibata, and Y. Arakawa Nosocomial transmisin of CTX-M-2 beta-lactamase producing Acinetobacter baumannii in a neurosurgery ward J Clin Microbiol 42 2004 3978 3984
79. A. Endemiani, F. Luzzaro, R. Migliavacca, E. Mantengoli, A.M. Hujer, and K.M. Hujer Spread in an italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase Antimicrob Agents Chemother 51 2007 2211 2214
80. T. Naas, F. Namdari, H. Rglier-Poupet, C. Poyart, and P. Nordmann Panresistant extended-spectrum beta-lactamase SHV-5-producing Acinetobacter baumannii from New York city J Antimicrob Chemother 60 2007 1174 1176
81. N. Al Naiemi, B. Duim, P.H.M. Savelkoul, L. Spanjaard, E. de Jonge, and A. Bart Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology J Clin Microbiol 43 2005 4862 4864
82. L. Poirel, O. Menuteau, N. Agoli, C. Cattoen, and P. Nordmann Outbreak of extended-spectrum beta-lactamase VEB-1 producing isolates of Acinetobacter baumannii in a French hospital J Clin Microbiol 41 2003 3542 3547
83. M. Ruiz, S. Mart, F. Fernndez-Cuenca, A. Pascual, and J. Vila High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain Clin Microbiol Infect 13 2007 1192 1198
84. P.G. Higgins, L. Poirel, M. Lehman, P. Nordmann, and H. Seifert OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii Antimicrob Agents Chemother 53 2009 5035 5038
85. T.R. Walsh, M.A. Toleman, J. Poirel, and P. Nordmann Metallo-beta- lactamases: the quiet before the storm? Clin Microbiol Rev 18 2005 306 325
86. J. Vila, S. Mart, and J. Snchez-Cspedes Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii J Antimicrob Chemother 59 2007 1201 1215
87. J. Vila, J. Ruiz, M.M. Navia, B. Becerril, I. Garcia, and S. Perrea Spread of amikacin resistance in Acinetobacter baumannii strains isolated in Spain due to an epidemic strain J Clin Microbiol 37 1999 758 761
88. A. Nemec, L. Dolzani, S. Brisse, P. van den Broek, and L. Dijkshoorn Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones J Med Microb 53 2004 1233 1240
89. S. Magnet, P. Courvalin, and T. Lambert Resistance-Nodulation-Cell Division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454 Antimicrob Agents Chemother 45 2001 3375 3380
90. P.G. Higgins, H. Wisplinghoff, D. Stefanik, and H. Seifert Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts Turing an outbreak of Acinetobacter baumannii J Antimicrob Chemother 54 2004 821 823
91. J. Vila, J. Ruiz, P. Goi, and M.T. Jimenez de Anta Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii Antimicrob Agents Chemother 39 1995 1201 1203
92. J. Vila, J. Ruiz, P. Goi, and M.T. Jimenez de Anta Quinolone resistance in the topoisomerase IV parC gene of Acinetobacter baumannii J Antimicrob Chemother 39 1997 757 762
93. J. Vila, A. Ribera, F. Marco, J. Ruiz, J. Mensa, and J. Chaves Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates J Antimicrob Chemother 49 2002 471 477
94. A. Ribera, J. Ruiz, M.T. Jimenez de Anta, and J. Vila Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates J Antimicrob Chemother 49 2002 697 702
95. M. Denton, and K.G.M. Kerr Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia Clin Microb Rev 11 1998 57 80
96. A. Alonso, and J.L. Martnez Cloning and characterization of SmeDEF, a novel efflux pump from Stenotrophomonas maltophilia Antimicrob Agents Chemother 44 2000 3079 3086
97. J. Vila, and J.L. Martinez Clinical impact of the over-expression of efflux pump in nonfermentative Gram-negative bacilli, development of efflux pump inhibitors Curr Drug Targets 9 2008 797 807
98. A. Ribera, A. Domenech-Snchez, J. Ruiz, V.J. Bened, M.T. Jimenez de Anta, and J. Vila Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in epdiemiological unrelated Stenotrophomonas maltophilia clinical isolates [en prensa] Microb Drug Resist 2002
99. S. Valdezate, A. Vindel, A. Echeita, F. Baquero, and R. Cantn Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility Antimicrob Agents Chemother 46 2002 665 671
100. M.B. Snchez, A. Hernndez, J.M. Rodrguez-Martnez, L. Martnez-Martnez, and J.L. Martnez Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants BMC Microbiol 8 2008 148
101. M.B. Snchez, and J.L. Martnez SmQnr contribuyes to intrnsic resistance to quinolones in Stenotrophomonas maltophilia Antimicrob Agents Chemother 54 2010 580 581
102. A. Ribera, A. Jurado, J. Ruiz, F. Marco, O. Del Valle, and J. Mensa In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and abscence of reserpine Diag Microbiol Infect Dis 42 2002 123 128
103. S. Valdezate, A. Vindel, E. Loza, F. Baquero, and R. Cantn Antimicrobi al susceptibilities of unique Stenotrophomonas maltophilia clinical strains Antimicrob Agents Chemother 45 2001 1581 1584